JUNFUTURE: Closes RMB 10M-Plus Pre-A, Builds GMP Capacity

On 16 November 2026, JunFuture closed a pre-A round of above RMB 10 million from Taizhou Huayin Financial Investment and the Taizhou Angel Investment Fund

NewTimeSpace News: On 16 November 2026, JunFuture (Jiangsu) Biomedicine Co., Ltd. (JunFuture, unlisted) closed a pre-A round of above RMB 10 million, invested by Taizhou Huayin Financial Investment and the Taizhou Angel Investment Fund; the exact amount and post-money valuation were not disclosed. Proceeds will mainly fund core pipeline development and GMP capacity construction plus registration filings for the first-phase fluorocarbon active pharmaceutical ingredient and pharmaceutical excipient project in Taizhou.

JunFuture was founded in 2021 and is headquartered in the Nanjing Jiangbei New Area biotech valley, with R&D and production sites in Zibo, Shandong and Taizhou, Jiangsu. Its team is led by a chief scientist of a National 973 Programme project, senior experts from the Chinese Medical Association and a highly cited researcher from MIT; founder Cheng Yuhao has been named a candidate for Shandong's Taishan industry entrepreneurship talent programme. The company builds on fluorocarbon medicine and operates at both ends of the chain.

Upstream, it develops processes for medical fluorocarbon APIs and builds large-scale cGMP capacity; downstream it develops innovative drugs and devices across four platforms, namely injectables, eye drops, topical products and inhalation. Medical fluorocarbons are surface-fluorinated small-molecule alkanes with biological inertness and high gas solubility, long used in vitreoretinal tamponade and contrast imaging. The company says its proprietary continuous-flow synthesis process has enabled self-controlled industrialisation of medical fluorocarbon, and that its portfolio includes Antifei universal artificial blood, Aofuming artificial tears, Fuling light-guiding gel and wound dressings, with consumer products such as Moudi fluorocarbon eye drops. It names NuvOX, Novaliq and Fluoron as overseas benchmarks.

The Taizhou site sits in the Taizhou Medical Hi-Tech Zone, which the company says offers concentrated API production capacity and supporting services. Huayin Financial Investment said the project fills a gap in local high-end medical fluorocarbon capacity and will build an industrial base around continuous-flow synthesis. The Taizhou Angel Investment Fund said the company holds core medical fluorocarbon manufacturing processes and covers ophthalmology and artificial blood, positioning it in an upstream import-substitution segment.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.